Encompass Health Co. (NYSE:EHC) Shares Acquired by Tower Research Capital LLC TRC

Tower Research Capital LLC TRC lifted its position in shares of Encompass Health Co. (NYSE:EHC - Free Report) by 139.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 10,598 shares of the company's stock after acquiring an additional 6,169 shares during the quarter. Tower Research Capital LLC TRC's holdings in Encompass Health were worth $979,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in EHC. MassMutual Private Wealth & Trust FSB boosted its position in shares of Encompass Health by 87.8% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 293 shares of the company's stock worth $27,000 after purchasing an additional 137 shares in the last quarter. Transce3nd LLC acquired a new stake in shares of Encompass Health in the fourth quarter valued at about $40,000. CBIZ Investment Advisory Services LLC boosted its holdings in Encompass Health by 38.7% during the fourth quarter. CBIZ Investment Advisory Services LLC now owns 455 shares of the company's stock worth $42,000 after buying an additional 127 shares in the last quarter. Tompkins Financial Corp acquired a new position in Encompass Health during the fourth quarter worth about $46,000. Finally, V Square Quantitative Management LLC increased its holdings in Encompass Health by 43.8% in the fourth quarter. V Square Quantitative Management LLC now owns 581 shares of the company's stock valued at $54,000 after buying an additional 177 shares in the last quarter. 97.25% of the stock is owned by hedge funds and other institutional investors.

Encompass Health Trading Down 0.6 %

Shares of NYSE:EHC traded down $0.75 during midday trading on Thursday, reaching $116.24. The company's stock had a trading volume of 227,388 shares, compared to its average volume of 680,373. The firm has a market cap of $11.71 billion, a price-to-earnings ratio of 26.10, a price-to-earnings-growth ratio of 2.31 and a beta of 0.87. The business has a 50 day moving average price of $101.07 and a 200 day moving average price of $98.96. Encompass Health Co. has a 1 year low of $82.38 and a 1 year high of $117.52. The company has a quick ratio of 1.04, a current ratio of 1.05 and a debt-to-equity ratio of 0.84.

Encompass Health (NYSE:EHC - Get Free Report) last posted its quarterly earnings results on Thursday, April 24th. The company reported $1.37 EPS for the quarter, beating the consensus estimate of $1.19 by $0.18. The company had revenue of $1.46 billion during the quarter, compared to analysts' expectations of $1.43 billion. Encompass Health had a return on equity of 17.56% and a net margin of 8.48%. The firm's revenue was up 10.6% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.12 EPS. Research analysts forecast that Encompass Health Co. will post 4.8 EPS for the current year.

Encompass Health Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, July 15th. Shareholders of record on Tuesday, July 1st will be paid a dividend of $0.17 per share. This represents a $0.68 dividend on an annualized basis and a yield of 0.59%. Encompass Health's dividend payout ratio is currently 14.05%.

Analysts Set New Price Targets

EHC has been the topic of several recent research reports. KeyCorp boosted their price objective on shares of Encompass Health from $120.00 to $122.00 and gave the stock an "overweight" rating in a research report on Friday, April 25th. StockNews.com raised shares of Encompass Health from a "hold" rating to a "buy" rating in a report on Friday, April 25th. William Blair reissued an "outperform" rating on shares of Encompass Health in a research note on Friday, February 7th. Truist Financial reiterated a "buy" rating and set a $135.00 target price (up previously from $116.00) on shares of Encompass Health in a report on Monday. Finally, Barclays upped their price objective on Encompass Health from $118.00 to $129.00 and gave the company an "overweight" rating in a research report on Friday, April 25th. Nine investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, Encompass Health has a consensus rating of "Buy" and a consensus price target of $120.86.

Insider Buying and Selling at Encompass Health

In related news, CAO Andrew L. Price sold 5,042 shares of Encompass Health stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $98.29, for a total value of $495,578.18. Following the transaction, the chief accounting officer now owns 69,164 shares in the company, valued at approximately $6,798,129.56. This trade represents a 6.79 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP John Patrick Darby sold 10,000 shares of Encompass Health stock in a transaction dated Tuesday, April 29th. The shares were sold at an average price of $114.79, for a total value of $1,147,900.00. Following the completion of the transaction, the executive vice president now directly owns 79,710 shares in the company, valued at $9,149,910.90. This represents a 11.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 2.10% of the stock is owned by company insiders.

Encompass Health Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.